At the SOC distribution, the highest report volumes occurred in general disorders and administration site conditions (12,940 cases), injury, poisoning, and procedural complications (5,503 cases), and gastrointestinal disorders (4,346 cases), collectively representing 48.7% of all SOC-classified reports, indicating a predominant systemic impact of TNF-α inhibitors in pediatric populations. This evidence concerns the gene TNF and digestive system disorder.